Literature DB >> 24163369

Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter.

Nancy H Nabilsi1, Daniel J Ryder, Ashley C Peraza-Penton, Rosha Poudyal, David S Loose, Michael P Kladde.   

Abstract

Genome-scale mapping suggests that the function of DNA methylation varies with genomic context beyond transcriptional repression. However, the use of DNA-demethylating agents (e.g. 5-aza-2'-deoxycytidine (5aza-dC)) to study epigenetic regulation often focuses on gene activation and ignores repression elicited by 5aza-dC. Here, we show that repression of NEK2, which encodes the never in mitosis A (NIMA)-related kinase, by 5aza-dC is context-specific as NEK2 transcript levels were reduced in HCT116 colon cancer cells but not in isogenic p53(-/-) cells. Bisulfite sequencing showed that DNA methylation was restricted to the distal region of the NEK2 promoter. Demethylation by 5aza-dC was associated with increased accessibility to micrococcal nuclease, i.e. nucleosome depletion. Conversely, methyltransferase accessibility protocol for individual templates (MAPit) methylation footprinting showed that nucleosome occupancy and DNA methylation at the distal promoter were significantly increased in p53(-/-) cells, suggesting dynamic regulation of chromatin structure at this region by p53 in HCT116 cells. Stabilization of endogenous p53 by doxorubicin or ectopic expression of p53, but not a p53 DNA-binding mutant, decreased NEK2 expression. Chromatin immunoprecipitation demonstrated direct and specific association of p53 with the distal NEK2 promoter, which was enhanced by doxorubicin. Luciferase reporters confirmed that this region is required for p53-mediated repression of NEK2 promoter activity. Lastly, modulation of p53 abundance altered nucleosome occupancy and DNA methylation at its binding region. These results identify NEK2 as a novel p53-repressed gene, illustrate that its repression by 5aza-dC is specific and associated with nucleosome reorganization, and provide evidence that identification of partially methylated regions can reveal novel p53 target genes.

Entities:  

Keywords:  Chromatin Regulation; Chromatin Structure; DNA Methylation; Epigenetics; MAPit; NEK2; Nucleosome; p53

Mesh:

Substances:

Year:  2013        PMID: 24163369      PMCID: PMC3861643          DOI: 10.1074/jbc.M113.523837

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Transcriptional repression of the anti-apoptotic survivin gene by wild type p53.

Authors:  William H Hoffman; Siham Biade; Jack T Zilfou; Jiandong Chen; Maureen Murphy
Journal:  J Biol Chem       Date:  2001-11-19       Impact factor: 5.157

2.  E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints.

Authors:  Bing Ren; Hieu Cam; Yasuhiko Takahashi; Thomas Volkert; Jolyon Terragni; Richard A Young; Brian David Dynlacht
Journal:  Genes Dev       Date:  2002-01-15       Impact factor: 11.361

3.  Modulation of DNA binding protein affinity directly affects target site demethylation.

Authors:  I G Lin; T J Tomzynski; Q Ou; C L Hsieh
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

4.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors.

Authors:  Michael L Whitfield; Gavin Sherlock; Alok J Saldanha; John I Murray; Catherine A Ball; Karen E Alexander; John C Matese; Charles M Perou; Myra M Hurt; Patrick O Brown; David Botstein
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

5.  Nek2 as a novel molecular target for the treatment of breast carcinoma.

Authors:  Nobuyuki Tsunoda; Toshio Kokuryo; Koji Oda; Takeshi Senga; Yukihiro Yokoyama; Masato Nagino; Yuji Nimura; Michinari Hamaguchi
Journal:  Cancer Sci       Date:  2009-01       Impact factor: 6.716

6.  Comparative epigenomics of human and mouse mammary tumors.

Authors:  Berna Demircan; Lisa M Dyer; Mallory Gerace; Edward K Lobenhofer; Keith D Robertson; Kevin D Brown
Journal:  Genes Chromosomes Cancer       Date:  2009-01       Impact factor: 5.006

7.  Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues.

Authors:  Xiao-Long Qiu; Guideng Li; Guikai Wu; Jiewen Zhu; Longen Zhou; Phang-Lang Chen; A Richard Chamberlin; Wen-Hwa Lee
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

8.  Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas.

Authors:  Federica Barbagallo; Maria P Paronetto; Renato Franco; Paolo Chieffi; Susanna Dolci; Andrew M Fry; Raffaele Geremia; Claudio Sette
Journal:  J Pathol       Date:  2009-02       Impact factor: 7.996

9.  Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study.

Authors:  Annika Brendle; Andreas Brandt; Robert Johansson; Kerstin Enquist; Göran Hallmans; Kari Hemminki; Per Lenner; Asta Försti
Journal:  Eur J Cancer       Date:  2008-11-12       Impact factor: 9.162

10.  Effects of CpG methylation on recognition of DNA by the tumour suppressor p53.

Authors:  Miriana Petrovich; Dmitry B Veprintsev
Journal:  J Mol Biol       Date:  2008-12-06       Impact factor: 5.469

View more
  12 in total

Review 1.  Role of E2Fs and mitotic regulators controlled by E2Fs in the epithelial to mesenchymal transition.

Authors:  Shirley Jusino; Harold I Saavedra
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-01

Review 2.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 3.  Role of NEK2A in human cancer and its therapeutic potentials.

Authors:  Jiliang Xia; Reinaldo Franqui Machin; Zhimin Gu; Fenghuang Zhan
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

4.  The transcription factor p53: not a repressor, solely an activator.

Authors:  Martin Fischer; Lydia Steiner; Kurt Engeland
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2.

Authors:  Byung-Kwon Choi; Tajhal Dayaram; Neha Parikh; Angela D Wilkins; Meena Nagarajan; Ilya B Novikov; Benjamin J Bachman; Sung Yun Jung; Peter J Haas; Jacques L Labrie; Curtis R Pickering; Anbu K Adikesavan; Sam Regenbogen; Linda Kato; Ana Lelescu; Christie M Buchovecky; Houyin Zhang; Sheng Hua Bao; Stephen Boyer; Griff Weber; Kenneth L Scott; Ying Chen; Scott Spangler; Lawrence A Donehower; Olivier Lichtarge
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-28       Impact factor: 11.205

Review 6.  Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.

Authors:  Erin Flynt; Kamlesh Bisht; Vinidhra Sridharan; María Ortiz; Fadi Towfic; Anjan Thakurta
Journal:  Cells       Date:  2020-01-24       Impact factor: 6.600

7.  Performance of Different Analytical Software Packages in Quantification of DNA Methylation by Pyrosequencing.

Authors:  Chiara Grasso; Morena Trevisan; Valentina Fiano; Valentina Tarallo; Laura De Marco; Carlotta Sacerdote; Lorenzo Richiardi; Franco Merletti; Anna Gillio-Tos
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

Review 8.  Census and evaluation of p53 target genes.

Authors:  M Fischer
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

9.  Characterization of Lgr5+ Progenitor Cell Transcriptomes after Neomycin Injury in the Neonatal Mouse Cochlea.

Authors:  Shasha Zhang; Yuan Zhang; Pengfei Yu; Yao Hu; Han Zhou; Lingna Guo; Xiaochen Xu; Xiaocheng Zhu; Muhammad Waqas; Jieyu Qi; Xiaoli Zhang; Yan Liu; Fangyi Chen; Mingliang Tang; Xiaoyun Qian; Haibo Shi; Xia Gao; Renjie Chai
Journal:  Front Mol Neurosci       Date:  2017-07-04       Impact factor: 5.639

Review 10.  The Rich World of p53 DNA Binding Targets: The Role of DNA Structure.

Authors:  Václav Brázda; Miroslav Fojta
Journal:  Int J Mol Sci       Date:  2019-11-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.